https://doi.org/10.55788/657884ed
“You already know that AF is associated with a higher risk of adverse cardiovascular events, and alcohol drinkers are at an increased risk of recurrent AF episodes; however, the role of alcohol on hard clinical endpoints in the AF population is still uncertain,” Dr Alireza Oraii (Population Health Research Institute, Canada) introduced his research [1].
The cross-sectional study analysed data from the global RE-LY AF Registry containing information from 47 different countries on 1-year outcomes of AF patients who visited emergency rooms. Data on self-reported quantities of alcohol consumption from 14,058 patients were included (mean age 66 years and 48% women). The assessment was performed according to 4 categories, i.e. abstainers, light drinkers (i.e. less than 7 standard drinks per week), moderate drinkers (i.e. 7–13 standard drinks per week), and heavy drinkers (at least 14 standard drinks per week). Endpoints after 1 year included stroke or systemic embolism, major bleeding events, hospitalisation for HF, and all-cause mortality.
Most of just over 12,000 participants did not drink any alcohol and 359 were heavy drinkers. Concerning stroke/systemic embolism, no significant differences were found when comparing each of the alcohol-drinking categories to the non-drinkers. For the 1-year odds of major bleeding, similar results were found for low, moderate, and heavy alcohol consumption versus abstinence.
“Interestingly, our data also suggested that light to moderate drinking habits were associated with significantly lower odds of HF hospitalisation and all-cause mortality,” Dr Oraii added. Light and moderate alcohol intake led to an odds ratio (OR) of 0.75 (95% CI 0.59–0.95) and OR 0.57 (95% CI 0.38–0.85), respectively, compared with no alcohol consumed. Furthermore, the likelihood of all-cause mortality was significantly reduced in those who drank light and moderate versus abstainers: OR 0.42 (95% CI 0.30–0.58) and OR 0.42 (95% CI 0.26–0.68).
“The evidence suggests that alcohol intake in moderation is not associated with excess odds of thromboembolic and major bleeding events in patients with AF and may even reduce odds of mortality and HF hospitalisation. However, a randomised controlled trial will need to be performed to solidify the evidence,” Dr Oraii concluded.
- Oraii A, et al. Alcohol consumption and cardiovascular outcomes in patients with atrial fibrillation; a RE-LY AF registry analysis. EA.APS. P270, AHA Scientific Sessions 2022, 05–07 November, Chicago, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« Periodontitis: An independent risk factor for AF Next Article
Higher LDL-cholesterol levels linked to higher CVD mortality risk in the elderly »
« Periodontitis: An independent risk factor for AF Next Article
Higher LDL-cholesterol levels linked to higher CVD mortality risk in the elderly »
Table of Contents: AHA 2022
Featured articles
What Is New in Heart Failure
Torsemide not superior to furosemide after hospitalisation for heart failure
IRONMAN failed primary endpoint but shows potential long-term benefits of iron repletion in HF patients
Up-titration of HF therapies following HF discharge saves lives
Hypertension: Novel Developments
The endothelin system: a new target for resistant high blood pressure
Can renal denervation lower BP on top of antihypertensive drugs?
Quadruple, ultra-low-dose treatment did not meet primary endpoint in hypertension
Mindfulness programme contributes to office blood pressure lowering
Interventional Cardiology in 2022
Grafting with the radial vein: an underrated option in CABG surgery?
Extracorporeal membrane oxygenation not superior to conservative therapy in cardiogenic shock
Surgery with adequate saphenous vein partly better than endovascular treatment in CLTI
Arrhythmia – State of the Art
First-line ablation limits progression to persistent AF
Doubling the dose of self-administered etripamil terminates PSVT
Novel Developments in Primary and Secondary Prevention
Grafting with the radial vein: an underrated option in CABG surgery?
Digitally delivered cognitive behavioural therapy successful in type 2 diabetes
Empagliflozin reduces risk of kidney disease progression and CV events in patients with CKD
RESPECT-EPA misses primary endpoint but hints towards improvements in CV outcomes by EPA
Pemafibrate fails to reduce cardiovascular events in diabetes but may benefit the liver
Dietary supplements not effective in lowering LDL-C, use of low-dose statins encouraged
No sex differences in lipid-lowering effect and treatment benefit of PCSK9 inhibitors
COVID-19 and the Heart
‘No’ to routine use of rivaroxaban in outpatients with COVID-19
COVID-19 pandemic: Older adults and those affected by the delta variant experienced increased cardiovascular morbidity and mortality
COVID-19 mRNA vaccination does not amplify risk of cardiovascular hospitalisation
Best of the Posters
Higher LDL-cholesterol levels linked to higher CVD mortality risk in the elderly
AF: Moderate alcohol intake possibly associated with a reduced mortality risk
Periodontitis: An independent risk factor for AF
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com